Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of venetoclax + decitabine in relapsed/refractory adult T-acute lymphoblastic leukemia/lymphoma
KCT0010455Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, decitabine in t-cell acute lymphoblastic leukemia (T-ALL), T-lymphoblastic lymphoma (T-LBL), sponsored by Boryung. Planned start May 2025; status: not yet recruiting.
02
Drugs
venetoclaxdecitabine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on KCT0010455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010455.